Search clinical trials for: DN-101 (calcitriol)

Total 6328 results

Flame Biosciences

Withdrawn

FL- 101 Study in Non-Metastatic MIBC

Muscle Invasive Bladder Carcinoma
Abeona Therapeutics, Inc

Terminated

A Long-term Follow-up Study of Patients With MPS IIIB Treated With ABO-101

Mucopolysaccharidosis III-B

United States, Germany, France
AL-S Pharma

Unknown

A Study to Evaluate AP-101 in Familial and Sporadic Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

Canada
United BioSource, LLC
AveXis, Inc.

Approved for marketing

AveXis Managed Access Program Cohort for Access to AVXS-101

Spinal Muscular Atrophy

United States
Curis, Inc.

Terminated

Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of Orally Administered CUDC-101 in Cancer Patients

Cancer

United States
Minerva Neurosciences

Completed

A Pharmacokinetic Study of Modified Release (MR) Formulations of MIN-101 in Healthy Subjects

Healthy Subjects

Ireland
Healthpoint

Completed

Cumulative Irritation Potential of 828 Ointment

Healthy Volunteers

United States
Healthpoint

Terminated

Evaluation of Effects of HP828-101 for Moisture Associated Skin Damage

Skin Abnormalities

United States
Norgine

Completed

A Study in Healthy Male Subjects Designed to Assess the Mass Balance Recovery and Pharmacokinetics of 14C TZP-101

Postoperative Ileus

United Kingdom
M.D. Anderson Cancer Center
Alaunos Therapeutics

Completed

Phase I Trial of ZIO-101 in Patients With Solid Tumors

Solid Tumors

United States
Bioray Laboratories
Xiangya Hospital of Central South University; First Affiliated Hospital of... and other collaborators

Enrolling by invitation

Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-Thalassemia

Beta-Thalassemia

China
Dynavax Technologies Corporation
Merck Sharp & Dohme LLC

Terminated

A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Metastatic Melanoma | Head Neck Cancer

United States, Germany, New Zealand, Australia
Gilead Sciences

Completed

Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma

Hodgkin Lymphoma

United States
Dana-Farber Cancer Institute
Gilead Sciences

Terminated

Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia

Waldenstrom's Macroglobulinemia

United States
Bioray Laboratories
Chinese Academy of Medical Sciences

Not yet recruiting

Clinical Study on the Safety and Efficacy of BRL-101 in the Treatment of Sickle Cell Disease

Sickle Cell Disease
Postgraduate Institute of Dental Sciences Rohtak

Completed

Effect of Systemic Administration of Vitamin D on the Rate of Orthodontic Tooth Movement - A Randomized Control Trial

Angle Class I

India
David Bushnell
VA Office of Research and Development

Completed

Combination Targeted Radiotherapy in Neuroendocrine Tumors

Neuroendocrine Tumors

United States
Aclaris Therapeutics, Inc.

Completed

Dose-Response Profile of A-101 in Subjects With Seborrheic Keratosis

Seborrheic Keratosis

United States
Emerald Health Pharmaceuticals

Suspended

Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Relapsing Forms of Multiple Sclerosis

Relapsing Forms of Multiple Sclerosis

United States, Australia
Scioderm, Inc.
Food and Drug Administration (FDA); Amicus Therapeutics

Terminated

Open-Label Extension Study to Evaluate the Safety of SD-101 Cream in Participants With Epidermolysis Bullosa

Epidermolysis Bullosa

United States
CuraSen Therapeutics, Inc.

Not yet recruiting

A Study of CST-103 Co-administered With CST-107 in Subjects With Parkinson's Disease Having Freezing of Gait (CLIN-012)

Freezing of Gait Symptoms in Parkinson's Disease

Australia
National Cancer Institute (NCI)

Terminated

Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma

Mesothelioma

United States
Gilead Sciences

Completed

Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas (DELTA)

Follicular Lymphoma | Marginal Zone Lymphoma | Lymphoplasmacytic Lymphoma | Small Lymphocytic Lymphoma

United States, United Kingdom, Italy, Germany, Poland, France
National Institute of Diabetes and Digestive and...
Boston University

Withdrawn

Study of Topical Calcitriol or Oral Calcitriol in Patients With Psoriasis

Psoriasis
Novacea
Schering-Plough

Suspended

A Study of Gemcitabine ± Erlotinib and DN-101 Versus Gemcitabine ± Erlotinib and Placebo in Patients With Advanced Pancreatic Cancer

Pancreatic Cancer

United States
Scioderm, Inc.
Amicus Therapeutics

Completed

ESSENCE Study: Efficacy and Safety of SD-101 Cream in Participants With Epidermolysis Bullosa

Epidermolysis Bullosa

Italy, Spain, Serbia, United States, Australia, Netherlands, Austria, Germany, Israel, Lithuania, France, United Kingdom, Poland
CuraSen Therapeutics, Inc.

Active, not recruiting

A Study of CST-103 Co-administered With CST-107 in Subjects With Neurodegenerative Disorders (CLIN-011)

Mild Cognitive Impairment, Lewy Body Dementia, Parkinson's Disease Rapid Eye Movement Sleep Behavior Disorder, Parkinson's Disease Dementia

Australia, New Zealand, United Kingdom
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia

Central Nervous System Neoplasm | Solid Neoplasm | Recurrent Acute Leukemia | Refractory Acute Leukemia | Infantile Fibrosarcoma

United States, Canada
Emerald Health Pharmaceuticals

Completed

To Evaluate the Safety and Tolerability, Pharmacokinetics, Food-effect and Pharmacodynamics of EHP-101 in Healthy Volunteers

Healthy

Australia
Ornovi, Inc.

Withdrawn

A First in Human Single and Multiple Ascending Dose and Open Label Food Effect Study of OR-101 in Healthy Subjects

Alopecia Areata

Australia
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors

Locally Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
Kythera Biopharmaceuticals

Completed

Open-Label Pharmacokinetic Study of Final Formulations of ATX-101

Healthy

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Marginal Zone Lymphoma | Waldenstrom Macroglobulinemia | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma and other conditions

United States
Galderma R&D

Completed

Efficacy and Safety Study of CD 2027 Spray in Subjects With Plaque-type Psoriasis

Psoriasis

United States, Canada
Gilead Sciences

Terminated

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease (Madison)

Myelofibrosis

United States
Gilead Sciences

Terminated

Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States, Spain, Belgium, Canada, United Kingdom, Australia, Denmark, Poland, Ireland, France, Sweden
LEO Pharma
Quintiles, Inc.

Completed

LEO 90105 Ointment in Japanese Subjects With Psoriasis

Psoriasis

Japan
AL-S Pharma

Recruiting

A Study to Evaluate, Safety, Tolerability, Pharmacodynamic (PD) Markers and Pharmacokinetics (PK) of AP-101 in Participants With Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

Korea, Republic of, United States, Canada, Germany, Sweden, Belgium
QurAlis Corporation

Completed

A Study Evaluating Safety, Tolerability, and Pharmacokinetics of QRL-101 in Healthy Participants

Healthy Volunteers

Netherlands
Veloxis Pharmaceuticals

Completed

A Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VEL-101

Healthy Volunteers

United States
Inversago Pharma Inc.

Completed

Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of INV-101 in Healthy Male and Female Subjects

Pharmacokinetic

Canada
Acanthas Pharma Inc

Withdrawn

A Study of Single Ascending Doses of STAR-101 in Healthy Participants

Healthy Volunteers
Alpine Immune Sciences, Inc.
Clinical Network Services (CNS) Pty Ltd

Completed

Adult Healthy Volunteers Study to Evaluate ALPN-101 Safety

Healthy Volunteers

Australia
Arava Bio Tech Ltd.

Unknown

Safety and Efficacy of Topical AR/101 Compared With Placebo, in Accelerating Granulation Tissue Formation of Hard-to-heal Wounds

Wounds | Other Ulcers Wounds and Skin Problems

Israel
Janssen Research & Development, LLC
Hoffmann-La Roche

Terminated

Safety and Efficacy of EVT 101 in Treatment-Resistant Depression

Depression

United States
Minerva Neurosciences

Completed

Pharmacokinetic Study of MIN-101 in Healthy Subjects

Schizophrenia

United Kingdom
Alaunos Therapeutics

Unknown

A Phase II Trial of ZIO-101 in Advanced Multiple Myeloma: Protocol SGL2001b

Multiple Myeloma

United States
Alaunos Therapeutics

Unknown

A Phase-II Trial of ZIO 101 in Advanced Hepatocellular Carcinoma

HEPATOCELLULAR CARCINOMA

United States
Mozart Therapeutics Australia Pty Ltd

Not yet recruiting

Safety, Pharmacokinetics, and Pharmacodynamics of MTX-101 in Healthy Adults and Patients

Type 1 Diabetes | Celiac Disease | Healthy Volunteers

Australia
CorrectSequence Therapeutics Co., Ltd

Recruiting

A Safety and Efficacy Study Evaluating CS-101 in Subjects With β-Thalassemia Major

Beta-Thalassemia Major

China

Search clinical trials for: DN-101 (calcitriol)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Algeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations